Response to Comments: Off-label Use of Rituximab and Rituximab Biosimilars

This document is a response to comments regarding off-label use of rituximab and biosimilars and does not itself define clinical coverage criteria. It announces a public comment/notice period beginning July 24, 2025, with the final determination effective September 7, 2025.

"This document does not establish or specify clinical coverage criteria for off-label use of rituximab or rituximab biosimilars."

Sign up to see full coverage criteria, indications, and limitations.